Financial reports
ARS
2023 FY
Annual report to shareholders
2 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
17 Apr 23
10-K
2022 FY
Annual report
2 Mar 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
Current reports
8-K
Unregistered Sales of Equity Securities
25 Apr 24
8-K
Spyre Therapeutics Announces $180 Million Private Placement
18 Mar 24
8-K
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
8-K
Entry into a Material Definitive Agreement
5 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Jan 24
8-K
Spyre Therapeutics Announces $180 Million Private Placement
8 Dec 23
8-K
Appoints CEO and Additional Directors, and Expands Leadership Team to
28 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Nov 23
8-K
Other Events
15 Nov 23
8-K
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
9 Nov 23
Registration and prospectus
S-1
IPO registration
18 Apr 24
POS AM
Prospectus update (post-effective amendment)
26 Mar 24
424B3
Prospectus supplement
18 Mar 24
POS AM
Prospectus update (post-effective amendment)
14 Mar 24
S-1/A
IPO registration (amended)
14 Mar 24
POS AM
Prospectus update (post-effective amendment)
5 Mar 24
S-1/A
IPO registration (amended)
1 Mar 24
S-8
Registration of securities for employees
29 Feb 24
424B3
Prospectus supplement
6 Feb 24
S-1/A
IPO registration (amended)
5 Feb 24
Proxies
DEF 14A
Definitive proxy
1 Apr 24
PRE 14A
Preliminary proxy
20 Mar 24
DEF 14A
Definitive proxy
26 Oct 23
PRER14A
Preliminary revised proxy
6 Oct 23
PRE 14A
Preliminary proxy
7 Aug 23
DEFA14A
Additional proxy soliciting materials
19 May 23
DEF 14A
Definitive proxy
17 Apr 23
PRE 14A
Preliminary proxy
7 Apr 23
DEF 14A
Definitive proxy
21 Apr 22
DEF 14A
Definitive proxy
22 Apr 21
Other
EFFECT
Notice of effectiveness
2 Apr 24
EFFECT
Notice of effectiveness
2 Apr 24
EFFECT
Notice of effectiveness
21 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
CORRESP
Correspondence with SEC
15 Nov 23
CORRESP
Correspondence with SEC
26 Oct 23
UPLOAD
Letter from SEC
24 Oct 23
UPLOAD
Letter from SEC
20 Oct 23
CORRESP
Correspondence with SEC
6 Oct 23
CORRESP
Correspondence with SEC
6 Oct 23
Ownership
4
Peter Evan Harwin
25 Apr 24
SC 13D/A
Fairmount Funds Management LLC
25 Apr 24
SC 13G/A
Avoro Capital Advisors LLC
23 Apr 24
SC 13G/A
FMR LLC
11 Mar 24
4
Cameron Turtle
20 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24